Last reviewed · How we verify

Nebulized 3% sodium chloride solution — Competitive Intelligence Brief

Nebulized 3% sodium chloride solution (Nebulized 3% sodium chloride solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucolytic/secretion mobilizer. Area: Pulmonology/Respiratory.

marketed Mucolytic/secretion mobilizer Pulmonology/Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Nebulized 3% sodium chloride solution (Nebulized 3% sodium chloride solution) — NYU Langone Health. Nebulized hypertonic saline draws fluid into the airways through osmotic gradient, hydrating secretions and promoting mucus clearance.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nebulized 3% sodium chloride solution TARGET Nebulized 3% sodium chloride solution NYU Langone Health marketed Mucolytic/secretion mobilizer

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucolytic/secretion mobilizer class)

  1. NYU Langone Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nebulized 3% sodium chloride solution — Competitive Intelligence Brief. https://druglandscape.com/ci/nebulized-3-sodium-chloride-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: